Johnson & Johnson: Changing health for humanity

We’re building a world where complex diseases are prevented and cured, treatments are smarter and less invasive—and solutions are ...

MYWOT

Child safety

Confidence

Trustworthiness

Confidence

18%

MALICIOUS CONTENT INDICATORS

Jnj.com most likely does not offer any malicious content.

Secure connection support

HTTPS

Jnj.com provides SSL-encrypted connection.

ADULT CONTENT INDICATORS

Jnj.com most likely does not offer any adult content.

Audience

Bounce rate

The accuracy of the provided data is based on the latest estimates available to us and can significantly differ from the real-life website stats, so should be taken with caution.
Time on site

The accuracy of the provided data is based on the latest estimates available to us and can significantly differ from the real-life website stats, so should be taken with caution.

03:40

AVG
Gender

The accuracy of the provided data is based on the latest estimates available to us and can significantly differ from the real-life website stats, so should be taken with caution.

Men

30%

Women

82.5%

Popular pages

Johnson & Johnson: Changing health for humanity
We’re building a world where complex diseases are prevented and cured, treatments are smarter and less invasive—and solutions are personal.
Using Data Science to Get New Treatments to Patients Faster
Johnson & Johnson's Sid Jain uses artificial intelligence to accelerate IBD clinical trials, aiming to bring new treatments to patients like himself.
What Are Clinical Trials? | Johnson & Johnson
Learn about the key aspects of clinical trials, the different clinical trial phases and the importance of clinical trial diversity.
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to
Investigational CD20-targeted CAR-Ts Enhance Janssen’s B-cell Malignancy PortfolioAgreement Deepens Janssen’s Leadership in Oncology and Hematology, and Accelerates Commitment to Delivering Transforma...
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
th Annual Global Healthcare Conference Johnson & Johnson to Participate in the Goldman Sachs 44 th Annual Global Healthcare Conference New Brunswick, NJ (May 10, 2023) - Johnson & Johnson (NYSE: JNJ) ...
First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction
Late-breaking data from the Phase 3 QUASAR Induction Study show statistically significant and clinically meaningful improvements among ulcerative colitis patients, including bio-naïve patients and tho...